Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis DOI Creative Commons
Adarsh Raja,

Saboor Ahmed,

Muhammad Basit Ali Siddiqui

и другие.

Frontiers in Psychiatry, Год журнала: 2024, Номер 15

Опубликована: Июль 5, 2024

Introduction Major depressive disorder (MDD), postpartum depression (PPD), and insomnia are neuropsychological conditions in which zuranolone is used to improve symptoms prognosis of the disorder. This meta-analysis aimed determine efficacy comparison other drugs for treating these conditions. Methods included patients aged between 18 75 years who were diagnosed with major or without administered treatment. Only randomized controlled trials (RCTs) included, animal studies excluded. The databases PubMed, Scopus, Cochrane, Clinicaltrials.gov, MeSH terms relevant keywords (Zuranolone) (Depression). Cochrane risk bias tool was quality assessment. Results eight RCTs that analyzed data from 2031 patients. revealed statistically significant changes Hamilton Depression Rating Scale (HAM-D), Montgomery-Åsberg (MADRS), Anxiety (HAM-A), treatment-emergent adverse effects (TEAE) scores PPD subgroup. HAM-D TEAEs also MDD subgroup, but MADRS, HAM-A, Bech-6 insignificant. Serious events insignificant all subgroups. Conclusion Meta-analysis found a improvement treatment, especially on day 15. suggests promising therapeutic option insomnia. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=459554 , identifier CRD42023459554.

Язык: Английский

Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder DOI Creative Commons
Andrew J. Cutler, Gregory W. Mattingly,

Vladimir Maletic

и другие.

Translational Psychiatry, Год журнала: 2023, Номер 13(1)

Опубликована: Июнь 26, 2023

The pathophysiology of major depressive disorder (MDD) is thought to result from impaired connectivity between key brain networks. Gamma-aminobutyric acid (GABA) the inhibitory neurotransmitter in brain, working primarily via GABA

Язык: Английский

Процитировано

64
Neuroanatomical changes observed over the course of a human pregnancy DOI Creative Commons
Laura Pritschet, Caitlin M. Taylor, Daniela Cossio

и другие.

Nature Neuroscience, Год журнала: 2024, Номер 27(11), С. 2253 - 2260

Опубликована: Сен. 16, 2024

Abstract Pregnancy is a period of profound hormonal and physiological changes experienced by millions women annually, yet the neural unfolding in maternal brain throughout gestation are not well studied humans. Leveraging precision imaging, we mapped neuroanatomical an individual from preconception through 2 years postpartum. Pronounced decreases gray matter volume cortical thickness were evident across brain, standing contrast to increases white microstructural integrity, ventricle cerebrospinal fluid, with few regions untouched transition motherhood. This dataset serves as comprehensive map human gestation, providing open-access resource for imaging community further explore understand brain.

Язык: Английский

Процитировано

23
Synthesis and clinical application of new drugs approved by FDA in 2023 DOI
Yatao Wang, Pengcheng Yang, Yanfeng Zhang

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 265, С. 116124 - 116124

Опубликована: Янв. 3, 2024

Язык: Английский

Процитировано

22
Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions DOI Creative Commons
Riah Patterson, Irina Balan, A. Leslie Morrow

и другие.

Neuropsychopharmacology, Год журнала: 2023, Номер 49(1), С. 67 - 72

Опубликована: Сен. 15, 2023

This article reviews novel neurosteroid therapeutics for post-partum depression, with a focus on their development, clinical trial data, current practices, and future directions in this exciting field. We discuss the impact of brexanolone several other neurosteroids, particularly as they relate to treatment postpartum depression (PPD) major depressive disorders outside perinatal period. There has been increasing interest GABA signaling modulation it pertains development altered circuity states. scientific underpinning served rationale initial brexanolone. review trials supporting its Food Drug Administration (FDA) approval first rapidly acting antidepressant specific PPD, subsequent program at an academic medical center, highlighting new research data from that site well challenges delivery I.V. drug. In addition hypothesis, we evidence demonstrating inhibits inflammatory post-infusion, suggesting may contribute etiology PPD. Finally, describe therapeutics, including oral agent, zuranolone, IV formulations ganaxolone. Ultimately, hope is these will provide fast-acting impairing improve our understanding underlying mechanisms disorders.

Язык: Английский

Процитировано

36
Nitrogen-Containing Heterocyclic Drug Products Approved by the FDA in 2023: Synthesis and biological activity DOI

Weijiang Luo,

Yiqi Liu,

Hui Qin

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2024, Номер 279, С. 116838 - 116838

Опубликована: Сен. 6, 2024

Язык: Английский

Процитировано

13
Novel insight into astrocyte-mediated gliotransmission modulates the synaptic plasticity in major depressive disorder DOI
Lan Lei, Yufei Wang,

Cong-Ya Chen

и другие.

Life Sciences, Год журнала: 2024, Номер 355, С. 122988 - 122988

Опубликована: Авг. 15, 2024

Язык: Английский

Процитировано

12
Clinical Utility of Zuranolone for Postpartum Depression: A Narrative Review DOI Creative Commons

Athanasia Giannopoulos,

Joshna Singh,

Kristina M. Deligiannidis

и другие.

Neuropsychiatric Disease and Treatment, Год журнала: 2025, Номер Volume 21, С. 93 - 105

Опубликована: Янв. 1, 2025

Peripartum depression (PPD) affects approximately one in every eight birthing individuals. Despite a high prevalence, PPD is underdiagnosed and undertreated. Several treatment options exist including psychotherapies, conventional serotonergic-based antidepressants alternative integrative medicine approaches. Rapid-acting neuroactive steroid-based have been studied approved the United States (US) for of adult females with PPD. Zuranolone first US Food Drug Administration oral antidepressant This narrative review reports on evidence clinical utility zuranolone treatment. In double-blind, randomized, placebo-controlled, trials, demonstrated rapid, statistically significant clinically meaningful improvements depressive symptoms. Most common adverse events reported use were somnolence, dizziness, sedation, headache. No changes vital signs, electrocardiogram or lab parameters observed. loss consciousness no increase suicidal ideation from baseline deaths seen studies. Secondary analyses that improves comorbid symptoms anxiety insomnia some measures health-related quality life. relevant infant dose lactation data suggest its compatible breastfeeding, though future research needed to measure potential effects breastfed infant. Key aspects decision-making patients are discussed.

Язык: Английский

Процитировано

1
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression DOI Creative Commons

Courtney M. Vecera,

Alan C. Courtes,

Gregory Jones

и другие.

Pharmaceuticals, Год журнала: 2023, Номер 16(11), С. 1572 - 1572

Опубликована: Ноя. 7, 2023

Treatment-resistant depression (TRD) is a term used to describe particular type of major depressive disorder (MDD). There no consensus about what defines TRD, with various studies describing between 1 and 4 failures antidepressant therapies, or without electroconvulsive therapy (ECT). That why TRD such growing concern among clinicians researchers, it explains the necessity for investigating novel therapeutic targets beyond conventional monoamine pathways. An imbalance two primary central nervous system (CNS) neurotransmitters, L-glutamate γ-aminobutyric acid (GABA), has emerged as having key role in pathophysiology TRD. In this review, we provide an evaluation comprehensive review investigational antidepressants targeting these systems, accessing their levels available evidence, mechanisms action, safety profiles. N-methyl-D-aspartate (NMDA) receptor antagonism shown most promise amongst glutamatergic targets, ketamine esketamine (Spravato) robustly generating responses across trials. Two specific NMDA-glycine site modulators, D-cycloserine (DCS) apimostinel, have also generated promising initial efficacy profiles, warranting further investigation. Combination dextromethorphan-bupropion (AXS-05/Auvelity) displays unique mechanism action demonstrated positive results applicability subpopulations cognitive dysfunction. Currently, GABA modulators appear be synthetic neurosteroid analogs GABAA modulation (such brexanolone). Overall, advances last decade exciting perspectives those who do not improve therapies. Of compounds reviewed here, three are approved by Food Drug Administration (FDA): Auvelity (dextromethorphan-bupropion) (MDD), brexanolone (Zulresso) post-partum (PPD). Notably, some concerns arisen brexanolone, which will detailed study.

Язык: Английский

Процитировано

18
Efficacy and safety of peri-partum Esketamine for prevention of post-partum depression in women undergoing caesarian section: A Meta-Analysis and Systematic Review of Randomized Controlled Trials DOI

Muhammad Anas Nayyer,

Suchna Meeral Khan,

Mohammad Umer

и другие.

Asian Journal of Psychiatry, Год журнала: 2024, Номер 97, С. 104090 - 104090

Опубликована: Май 21, 2024

Язык: Английский

Процитировано

8
Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov DOI Creative Commons

Eugenia D. Namiot,

Diana Smirnovová,

Aleksandr V. Sokolov

и другие.

Translational Psychiatry, Год журнала: 2024, Номер 14(1)

Опубликована: Июль 31, 2024

Abstract Major depressive disorder (MDD), commonly known as depression, affects over 300 million people worldwide of 2018 and presents a wide range clinical symptoms. The international trials registry platform (ICTRP) introduced by WHO includes aggregated data from ClinicalTrials.gov 17 other national registers, making it the largest trial platform. Here we analysed in ICTRP with aim providing comprehensive insights into on depression. Applying novel hidden duplicate identification method, 10,606 depression were identified ICTRP, ANZCTR being non- database at 1031 trials, followed IRCT 576 ISRCTN 501 CHiCTR 489 EUCTR 351 trials. top four most studied drugs, ketamine, sertraline, duloxetine, fluoxetine, consistent both groups, but had more for each drug compared to non-ClinicalTrials.gov group. Out 9229 interventional 663 unique agents identified, including approved drugs (74.5%), investigational (23.2%), withdrawn (1.8%), nutraceuticals (0.3%), illicit substances (0.2%). Both databases revealed that categories antidepressive (1172 659 non-ClinicalTrials.gov) nutrients, amino acids, chemical elements (250 non-ClinicalTrials.gov), indicating focus alternative treatments involving dietary supplements nutrients. Additionally, 26 targeting 16 different targets buprenorphine (opioid agonist), saredutant (NK2 antagonist), seltorexant (OX2 antagonist) frequently studied. This analysis addresses 40 treatment new classes like GABA modulators NMDA antagonists are offering prospects treating MDD, drug-resistant postpartum subtypes.

Язык: Английский

Процитировано

8